[New approaches to therapy in glomerulonephritis patients].
Before starting treatment of chronic glomerulonephritis it is desirable to determine the patient's drug sensitivity in vitro because in the absence of such sensitivity chemotherapy should be preceded by immunomodulation with tactivin or thymalin and 3-5 sessions of plasmapheresis to stimulate drug sensitivity. Further measures include prednisolone or cyclophosphamide intravenously for 3-5 days in a dose 300-500 followed by oral administration. Active treatment lasts for 4-8 weeks. After that the patients receive maintenance for 1-2 years.
Riabov
S I
SI
Rakitianskaia
I A
IA
Stavskaia
V V
VV
Nikitina
N A
NA
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology; D002908:Chronic Disease; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000494:pharmacology; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005921:Glomerulonephritis / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D005938:Glucocorticoids / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D009404:Nephrotic Syndrome / Q000097:blood / Q000188:drug therapy / Q000401:mortality; D011239:Prednisolone / Q000008:administration & dosage / Q000494:pharmacology; D012008:Recurrence; D013601:T-Lymphocytes / Q000187:drug effects; D013997:Time Factors
D000970:Antineoplastic Agents; D005938:Glucocorticoids; D003520:Cyclophosphamide; D011239:Prednisolone
Novye podkhody k terapii bol'nykh glomerulonefritom.